ASCO Direct™ GU 2024

Chairs: dr. Niven Mehra & dr. Andre Bergman

Oral Abstract Session A: Prostate Cancer

Voorzitters: dr. Niven Mehra & dr. Andre Bergman

[10 min] 19 BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm) 

[10 min] 18 CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) 

[10 min] LBA259 Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial 

[15 min] Discussie olv chairs 

Treatment Intensification: What To Do for Patients With Early Castration-Resistant Prostate Cancer Who Have Received Doublet or Triplet Therapy

Voorzitters: dr. Jorg Oddens & dr. André Bergman

[10 min] Sequencing Hormonal Therapies After Treatment Intensification 

[10 min] PSMA-Targeting and Radium-223 

[10 min] Is There a Role for Stereotactic Radiotherapy in Selected Patients With Metastatic Castrate-Resistant Prostate Cancer? 

[15 min] Discussie olv chairs: vragen bedenken voor interview 

Gastspreker: Silke Gillessen Sommer 

Onderwerp: Treatment Intensification: What To Do for Patients With Early Castration-Resistant Prostate Cancer Who Have Received Doublet or Triplet Therapy

 Voorzitter(s) Nederland: dr. Niven Mehra

Host in San Francisco: dr. Rik Somford 

Emerging Evidence in Localized and Recurrent Prostate Cancer

Rapid Oral Abstract Session A: Prostate Cancer

De-Escalation in Prostate Cancer: Can We Maintain Efficacy With Less Toxicity?

Voorzitters: dr. Floris Pos & dr. Jorg Oddens

[7 min] Setting the Stage: Biochemical Recurrence After Local Treatment for Prostate Cancer 

[15 min] Salvage Radiotherapy Options for Biochemical Recurrence After Local Treatment 

[12 min] Systemic Treatment of High-Risk Biochemical Recurrence

[5 min] 20 Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): The ACE study 

[5 min] 21 Differences in genomic, transcriptomic, and immune landscape of prostate cancer (PCa) based on site of metastasis (mets) 

[10 min] 15 Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study. 

[15 min] Discussie olv chairs

Oral Abstract Session B: Urothelial Carcinoma

Voorzitters: dr. Franchette van den Berkmortel & dr. Floris Pos

 [10 min] 539 Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab)

 [10 min] LBA531 AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation

 [10 min] LBA530 Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3

 [20 min] Bekijken opgenomen interview uit San Francisco

 Gast spreker: Michiel van der Heijden

Host in San Francisco: dr. Rik Somford

[10 min] Discussie 

Rapid Oral Abstract Session B: Urothelial Carcinoma

Role of Immunotherapy in Advanced Urothelial Carcinoma: Sequencing, Pairing, Rechallenging

Voorzitters: dr. Niven Mehra & dr. Jorg Oddens

 [5 min] 538 HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer

 [5 min] 540 FGFR3 mutated (FGFR3mut+) urothelial carcinoma of bladder (UCB) or upper tract (UTUC): A comparative genomic landscape study.

 [5 min] 632 Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC): Interim analysis of ANTICIPATE phase II trial

 [15 min] 528 Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial

 [15 min] Discussie 

The Shortage of Drugs for Urothelial Carcinoma: Why We Can’t Get What Our Patients Need and What We Can Do About This

Voorzitters: dr. Franchette van den Berkmortel & dr. Jorg Oddens 

[20 min] Bekijken opgenomen interview vanaf San Francisco 

Gast spreker: Joshua Meeks

Topic: Bacillus Calmette-Guerin Shortage: What’s on the Horizon to Replace?

 Gemcitabine TAR 200: what are the advantages compared to available therapies? What problems do you encounter?

Host in San Francisco: dr. Rik Somford

 [10 min] Discussie 

Voorzitters: dr. Jorg Oddens & dr. Franchette van den Berkmortel

door dr. Franchette van den Berkmortel

 [10 min] Discussie 

Voorzitters: dr. Jorg Oddens & dr. Floris Pos

 [10 min] Discussie 

Optimizing Treatment Strategies for Patients With Positive Pelvic/Retroperitoneal Lymph Nodes

Voorzitters: dr. Jorg Oddens & dr. Floris Pos

 [15 min] Surgical Therapeutic Role for Node-Positive Disease: Does It Make a Difference?

 [15 min] Total Clinical Response: Now What?

 [15 min] Biology of Tumor Types: Radiation Versus Surgery

 [15 min] 527 Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials

 [15 min] Discussie

Dr. Jorg Oddens & dr. Niven Mehra